FDA
6th December 2013

FDA AdComm Roll Call – 4 New Members!!

The Medical Imaging Drugs Advisory Committee welcomed Henry D. Royal, MD. Dr. Royal’s expertise is radiology and radiation countermeasures. He is currently Associate Director at the Mallinckrodt Institute of Radiology – Division of Nuclear Medicine in St. Louis, Missouri. 

FDA AdComm Roll Call – 4 New Members!!

For this edition of our FDA AdComm Roll Call, 4 new individuals have been welcomed into two advisory committees!!

The Medical Imaging Drugs Advisory Committee welcomed Henry D. Royal, MD. Dr. Royal’s expertise is radiology and radiation countermeasures. He is currently Associate Director at the Mallinckrodt Institute of Radiology – Division of Nuclear Medicine in St. Louis, Missouri.

Also, the Pulmonary-Allergy Drugs Advisory Committee welcomed 3 new members to its roster leaving only 1 vacancy. Looks like they needed more people to keep up with their busy meeting schedule! The new members are:

  • Steve N. Georas, MD, expert of pulmonary/critical care medicine. Dr. Georas is currently a Professor of Medicine at the University of Rochester Medical Center – Division of Pulmonary and Critical Care Medicine in Rochester, New York.
  • Dennis R. Ownby, MD, expert in pediatric allergy-immunology. Dr. Ownby is currently a Professor of Pediatrics at Georgia Regents University – Division of Allergy, Immunology and Rheumatology in Augusta, Georgia. 
  • Francis X. McCormack, MD, expert of pulmonary/critical care medicine. Dr. McCormack is currently Taylor Professor and Director at  University of Cincinnati School of Medicine – Division of Pulmonary, Critical Care and Sleep Medicine in Cincinnati, Ohio. 

Stay tuned for our next AdComm Roll Call Special where we will put the spotlight on the Pulmonary-Allergy Drugs Advisory Committee!!!

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

Interested in learning about ISS’ expert approach to Advisory Committee Meetings? Click below in order to find out for yourself!

Generic Blog CTA for Ad Comm Approach

 

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us